Spectrum Pharmaceuticals
SPPI
SPPI was delisted on the 31st of July, 2023.
124 hedge funds and large institutions have $416M invested in Spectrum Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 42 increasing their positions, 46 reducing their positions, and 16 closing their positions.
425% more call options, than puts
Call options by funds: $677K | Put options by funds: $129K
38% more capital inflows, than outflows
Capital inflows: $35.2M | Capital outflows: $25.6M
1.68% more ownership
Funds ownership: 67.78% → 69.46% (+1.7%)
9% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 46
3% less funds holding
Funds holding: 128 → 124 (-4)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
+$13.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.36M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.03M |
| 4 |
Renaissance Technologies
New York
|
+$2.56M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.31M |
| 2 |
Goldman Sachs
New York
|
-$2.42M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$1.72M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.62M |
| 5 |
BlackRock
New York
|
-$1.59M |
SPPI Hedge Fund Activity: Q2 2017 in Review
124 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Spectrum Pharmaceuticals (SPPI) for Q2 2017, worth a combined $416M — up 18% from $354M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SPPI and 12 opened new positions — a net loss of 4 holders — while 46 trimmed existing stakes and 42 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $13.2M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $4.31M sold.
- 124 institutional investors held Spectrum Pharmaceuticals (SPPI) as of Q2 2017, down from 128 in Q1 2017.
- Funds reported $416M of Spectrum Pharmaceuticals stock for Q2 2017, up 18% quarter-over-quarter.
- 12 funds opened new Spectrum Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of -4 holders.
- The largest Spectrum Pharmaceuticals buyer in Q2 2017 was Consonance Capital Management, an estimated $13.2M added.
- The largest Spectrum Pharmaceuticals seller in Q2 2017 was Acadian Asset Management, an estimated $4.31M sold.
Based on aggregated 13F filings for Q2 2017.